Your stem cells will never be younger: potency declines with age — and no technology restores it.
TL;DR
Marrow stem cells from donors 18–29 averaged 41 population doublings before exhaustion versus 24 for donors 68–81. Adipose cells show the same pattern: senescence 5.2% under 40 vs 12.2% over 50, doubling time 62 vs 89 hours. Senolytics remove senescent cells; they do not restore a young pool. Reprogramming can rewind age markers but not the mutations stem cells accumulate at roughly 40 per year. Bank now.
Why this matters if you're considering banking
Banking stores a sample of your cells as they are today. Expansion from that sample is what later produces a therapeutic dose. If the starting cells have already spent their doubling runway and carry a higher senescent fraction, every future dose is grown from a worse input. This is a sample-level claim, not a treatment claim.
Do stem cells lose potency with age?
Yes for the capacities banking depends on: population doublings, expansion headroom, and senescence burden. Differentiation after the fact is more mixed.
Aging of mesenchymal stem cells (Stenderup 2003)
Stenderup K, Justesen J, Clausen C, Kassem M · Bone · 2003
Donors 18–29: 41 ± 10 population doublings to exhaustion (n=6). Donors 68–81: 24 ± 11 (n=5). That is the expansion runway.
Limitation. Small donor panel (n=6 young, n=5 old); in vitro expansion, not a clinical outcome trial. Old-donor cells still formed mineralized matrix once differentiated.
Donor age negatively influences adipose MSC function (Choudhery 2014)
Choudhery MS, Badowski M, Muise A, Pierce J, Harris DT · Journal of Translational Medicine · 2014
Adipose-derived cells, Forever Labs’ tissue class: senescence 5.2% → 12.2% and doubling time 62 → 89 hours across the under-40 vs over-50 cohorts.
Limitation. Adipose tissue, not marrow; senescence measured in culture. Cohort ages skip 40–50. Individual results vary.
Aging of mesenchymal stem cells (Liu 2020)
Liu J, Ding Y, Liu Z, Liang X · Frontiers in Cell and Developmental Biology · 2020
Field-consensus review: MSC aging is described across labs; every rejuvenation strategy remains experimental.
Limitation. Narrative review, not a systematic review or RCT. Rejuvenation claims are mechanistic.
Senescence-associated secretory phenotype (Coppé 2008)
Coppé JP, Patil CK, Rodier F, et al. · PLoS Biology · 2008
SASP discovery: senescent cells secrete inflammatory factors that can spread the phenotype.
Limitation. Mechanistic / in vitro discovery paper, not a clinical MSC banking study.
Paracrine senescence (Acosta 2013)
Acosta JC, Banito A, Wuestefeld T, et al. · Nature Cell Biology · 2013
Paracrine senescence — the contagion mechanism, not just a cell-autonomous stall.
Limitation. Mechanistic / animal and cell-culture evidence; not a human MSC therapy trial.
Transplanted senescent cells impair function in vivo (Xu 2018)
Xu M, Pirtskhalava T, Farr JN, et al. · Nature Medicine · 2018
Transplantation arm: senescent cells impaired function in vivo. Senolytic removal is not restoration of a young pool.
Limitation. Mouse transplantation model. Senolytic removal ≠ restoration of a young MSC pool.
Tissue-specific mutation accumulation in human adult stem cells (Blokzijl 2016)
Blokzijl F, de Ligt J, Jager M, et al. · Nature · 2016
Human stem cells accumulate roughly 40 new mutations per year.
Limitation. Small-intestine, colon, and liver stem cells — not marrow or adipose MSCs. Rate is a field estimate, not a per-patient lab result.
Is differentiation capacity equally age-dependent?
No. That is the caveat that keeps this a High rather than an overstated grade. See evidence against.
Aging of mesenchymal stem cells (Stenderup 2003)
Stenderup K, Justesen J, Clausen C, Kassem M · Bone · 2003
The same Stenderup cultures: old-donor cells still formed mineralized matrix once they differentiated. Capacity to differentiate is not the same as remaining doublings.
Limitation. Small donor panel (n=6 young, n=5 old); in vitro expansion, not a clinical outcome trial. Old-donor cells still formed mineralized matrix once differentiated.
Phenotype, donor age and gender affect function of human bone marrow MSCs (Siegel 2013)
Siegel G, Kluba T, Hermanutz-Klein U, Bieback K, Northoff H, Schäfer R · BMC Medicine · 2013
Siegel 2013, 53-donor panel: differentiation capacity and trophic-factor secretion were age-independent. TODO: Mark to confirm full text.
Limitation. TODO for Mark: confirm this is the intended 53-donor panel. Differentiation independence does not contradict proliferation decline.
MSC aging systematic review, 2023 — chondrogenic decline in 4/14 studies; proliferation decline in 11/14
TODO — Mark to confirm · TODO · 2023
2023 systematic review: chondrogenic decline in only 4 of 14 studies; 11 of 14 agreed on proliferation/clonogenicity decline. DOI unverified.
Limitation. DOI not supplied in the v2 brief. Unverified until Mark confirms the full text and citation. Do not publish this card until then.
What would change our verdict
A controlled demonstration that an aged human MSC population can be restored to young-donor doubling capacity, senescence fraction, and mutation burden — not merely that senescent cells can be killed or that differentiation still occurs.
Why this confidence grade
Growth capacity, expansion headroom, and senescence burden decline near-unanimously. Per-cell differentiation is heterogeneous — Stenderup’s old-donor cells still formed mineralized matrix; Siegel 2013 found differentiation and trophic-factor secretion age-independent in a 53-donor panel; a 2023 systematic review found chondrogenic decline in only 4 of 14 studies while 11 of 14 agreed on proliferation/clonogenicity decline. The hypothesis is stated about potency-as-capacity, which is what banking and expansion actually depend on — that is why the grade is High, not a step higher that would erase the differentiation caveat.
Questions we hear
- Can't I just collect my cells later?
- You can, and we enroll adults at any eligible age. Waiting means the cells you store will have reduced doubling potential, more accumulated mutations (~40 per year in human stem cells), and a higher senescent fraction that can spread inflammatory signaling to neighboring cells. Banking at your youngest possible age is the sample you will expand from later.
- Can't future medicine fix my old cells?
- Senolytics remove senescent cells; they do not restore a young pool. Reprogramming can rewind age markers but does not remove mutations a cell has already accumulated. Whatever therapy arrives will work better, cheaper, and safer from younger autologous cells.
Reviewed by Mark Katakowski, PhD · Last reviewed August 26, 2026